Feedback

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations

Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Bertoglio, Federico;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Fühner, Viola;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Ruschig, Maximilian;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Heine, Philip Alexander; Abassi, Leila; Klünemann, Thomas; Rand, Ulfert;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Meier, Doris;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Langreder, Nora;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Steinke, Stephan;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Ballmann, Rico;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Schneider, Kai-Thomas;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Roth, Kristian Daniel Ralph; Kuhn, Philipp;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Riese, Peggy;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Schäckermann, Dorina;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Korn, Janin;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Koch, Allan; Chaudhry, M Zeeshan; Eschke, Kathrin; Kim, Yeonsu;
Affiliation/Institute
TU Braunschweig, Institut für Genetik
Zock-Emmenthal, Susanne;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Becker, Marlies;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Scholz, Margitta;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Moreira, Gustavo Marçal Schmidt Garcia;
ORCID
0000-0002-6931-5612
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Wenzel, Esther Veronika;
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Russo, Giulio; Garritsen, Hendrikus S P; Casu, Sebastian; Gerstner, Andreas; Roth, Günter; Adler, Julia; Trimpert, Jakob; Hermann, Andreas; Schirrmann, Thomas;
ORCID
0000-0001-8811-7390
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Dübel, Stefan; Frenzel, André; Van den Heuvel, Joop; Čičin-Šain, Luka;
ORCID
0000-0002-7041-9056
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Schubert, Maren;
ORCID
0000-0003-3418-6045
Affiliation/Institute
Institut für Biochemie, Biotechnologie und Bioinformatik, Abteilung Biotechnologie
Hust, Michael

The novel betacoronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) causes a form of severe pneumonia disease called coronavirus disease 2019 (COVID-19). To develop human neutralizing anti-SARS-CoV-2 antibodies, antibody gene libraries from convalescent COVID-19 patients were constructed and recombinant antibody fragments (scFv) against the receptor-binding domain (RBD) of the spike protein were selected by phage display. The antibody STE90-C11 shows a subnanometer IC50 in a plaque-based live SARS-CoV-2 neutralization assay. The in vivo efficacy of the antibody is demonstrated in the Syrian hamster and in the human angiotensin-converting enzyme 2 (hACE2) mice model. The crystal structure of STE90-C11 Fab in complex with SARS-CoV-2-RBD is solved at 2.0 Å resolution showing that the antibody binds at the same region as ACE2 to RBD. The binding and inhibition of STE90-C11 is not blocked by many known emerging RBD mutations. STE90-C11-derived human IgG1 with FcγR-silenced Fc (COR-101) is undergoing Phase Ib/II clinical trials for the treatment of moderate to severe COVID-19.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

Use and reproduction: